Relmada Therapeutics
RLMD
78 hedge funds and large institutions have $246M invested in Relmada Therapeutics in 2025 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 8 reducing their positions, and 1 closing their positions.
3,400% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 1
3,304% more call options, than puts
Call options by funds: $1.94M | Put options by funds: $57K
1,481% more capital invested
Capital invested by funds: $15.5M → $246M (+$230M)
175% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 8
77% more funds holding
Funds holding: 44 → 78 (+34)
25.22% more ownership
Funds ownership: 23.32% → 48.54% (+25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$24.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$9.78M |
| 4 |
O
OrbiMed
New York
|
+$8.75M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$6.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$281K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$187K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$115K |
| 4 |
RC
RBF Capital
San Francisco,
California
|
-$77.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$61.4K |
RLMD Hedge Fund Activity: Q4 2025 in Review
78 of the 8,276 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2025, worth a combined $246M — up 1,481% from $15.5M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new RLMD positions and 1 closed out — a net gain of 34 holders — while 22 added to existing stakes and 8 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $24.4M. The largest seller was AdvisorShares Investments, cutting an estimated $281K.
- 78 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2025, up from 44 in Q3 2025.
- Funds reported $246M of Relmada Therapeutics stock for Q4 2025, up 1,481% quarter-over-quarter.
- 35 funds opened new Relmada Therapeutics positions in Q4 2025 and 1 closed out, a net change of +34 holders.
- The largest Relmada Therapeutics buyer in Q4 2025 was Janus Henderson Group, an estimated $24.4M added.
- The largest Relmada Therapeutics seller in Q4 2025 was AdvisorShares Investments, an estimated $281K sold.
Based on aggregated 13F filings for Q4 2025.